Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B Wake, C Hyde, S Bryan, PM Barton, F Song, A Fry-Smith, C Davenport

Research output: Contribution to journalArticle

22 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-85
Number of pages85
JournalHealth Technology Assessment
Issue number3
Publication statusPublished - 2002

Cite this